U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ACHIRAL
Molecular Formula C23H22FN3O3
Molecular Weight 407.4383
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of CATEQUENTINIB

SMILES

Cc1cc2c(ccc(c2F)Oc3ccnc4cc(c(cc43)OC)OCC5(CC5)N)[nH]1

InChI

InChIKey=KSMZEXLVHXZPEF-UHFFFAOYSA-N
InChI=1S/C23H22FN3O3/c1-13-9-15-16(27-13)3-4-19(22(15)24)30-18-5-8-26-17-11-21(20(28-2)10-14(17)18)29-12-23(25)6-7-23/h3-5,8-11,27H,6-7,12,25H2,1-2H3

HIDE SMILES / InChI

Molecular Formula C23H22FN3O3
Molecular Weight 407.4383
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

AL3818 (anlotinib) is a receptor tyrosine kinase inhibitor targeting vascular endothelial growth factor receptors (VEGFR1, VEGFR2/KDR, and VEGFR3), stem cell factor receptor (C-kit), platelet-derived growth factor (PDGFβ), and fibroblast growth factor receptors (FGFR1, FGFR2, and FGFR3). Anlotibib is a kind of innovative medicines approved by State Food and Drug Administration(SFDA:2011L00661) which was researched by Jiangsu Chia-tai Tianqing Pharmaceutical Co., Ltd. Phase III development is underway for the treatment of thyroid cancer, gastric cancer, leiomyosarcoma; non-small cell lung cancer; synovial sarcoma; thyroid cancer etc.

Approval Year

Targets

Targets

Primary TargetPharmacologyConditionPotency
0.2 nM [IC50]
1.0 nM [IC50]
7.7 null [pIC50]
Conditions
PubMed

PubMed

TitleDatePubMed
Safety, pharmacokinetics, and antitumor properties of anlotinib, an oral multi-target tyrosine kinase inhibitor, in patients with advanced refractory solid tumors.
2016 Oct 4
Safety and Efficacy of the S-1/Temozolomide Regimen in Patients with Metastatic Neuroendocrine Tumors.
2018
Endometrial Cancers Harboring Mutated Fibroblast Growth Factor Receptor 2 Protein Are Successfully Treated With a New Small Tyrosine Kinase Inhibitor in an Orthotopic Mouse Model.
2018 Jan
Patents

Sample Use Guides

Anlotinib (AL3818) 12 mg orally administered once daily in 21-day cycles (14 days on treatment, 7 days off treatment)
Route of Administration: Oral
AN3CA cells appeared the most sensitive to AL3818 with an IC50 value of 84 nM. The other cell lines were approximately 28- to 550-fold less sensitive to AL3818. HEC1B had an IC50 value of 46 uM, and MFE296 cells were sensitive to AL3818, with an IC50 value of 2.9 uM compared with 3.2, 28.9, 29, and 40 uM for Ishikawa, MFE280, KLE, and HEC1A, respectively.
Substance Class Chemical
Created
by admin
on Sat Jun 26 09:23:45 UTC 2021
Edited
by admin
on Sat Jun 26 09:23:45 UTC 2021
Record UNII
GKF8S4C432
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
ANLOTINIB
Preferred Name English
CATEQUENTINIB
INN  
Official Name English
1-(((4-((4-FLUORO-2-METHYL-1H-INDOL-5-YL)OXY)-6-METHOXY-7-QUINOLINYL)OXY)METHYL)CYCLOPROPANAMINE
Systematic Name English
AL 3818
Code English
ALTN
Common Name English
AL3818
Code English
AL-3818
Code English
CATEQUENTINIB [WHO-DD]
Common Name English
CATEQUENTINIB [INN]
Common Name English
CYCLOPROPANAMINE, 1-(((4-((4-FLUORO-2-METHYL-1H-INDOL-5-YL)OXY)-6-METHOXY-7-QUINOLINYL)OXY)METHYL)-
Systematic Name English
Classification Tree Code System Code
NCI_THESAURUS C129825
Created by admin on Sat Jun 26 09:23:46 UTC 2021 , Edited by admin on Sat Jun 26 09:23:46 UTC 2021
FDA ORPHAN DRUG 576017
Created by admin on Sat Jun 26 09:23:46 UTC 2021 , Edited by admin on Sat Jun 26 09:23:46 UTC 2021
NCI_THESAURUS C1742
Created by admin on Sat Jun 26 09:23:46 UTC 2021 , Edited by admin on Sat Jun 26 09:23:46 UTC 2021
Code System Code Type Description
DRUG BANK
DB11885
Created by admin on Sat Jun 26 09:23:46 UTC 2021 , Edited by admin on Sat Jun 26 09:23:46 UTC 2021
PRIMARY
EVMPD
SUB192810
Created by admin on Sat Jun 26 09:23:46 UTC 2021 , Edited by admin on Sat Jun 26 09:23:46 UTC 2021
PRIMARY
NCI_THESAURUS
C138997
Created by admin on Sat Jun 26 09:23:46 UTC 2021 , Edited by admin on Sat Jun 26 09:23:46 UTC 2021
PRIMARY
FDA UNII
GKF8S4C432
Created by admin on Sat Jun 26 09:23:46 UTC 2021 , Edited by admin on Sat Jun 26 09:23:46 UTC 2021
PRIMARY
MANUFACTURER PRODUCT INFORMATION
ANLOTINIB
Created by admin on Sat Jun 26 09:23:46 UTC 2021 , Edited by admin on Sat Jun 26 09:23:46 UTC 2021
PRIMARY Anlotinib (AL3818) - MedKoo CAT NO.: 206058Description: Anlotinib, alos known as AL3818, is a receptor tyrosine kinase (RTK) inhibitor with potential antineoplastic and anti-angiogenic activities. Upon administration, anlotininib targets multiple RTKs, including vascular endothelial growth factor receptor type 2 (VEGFR2) and type 3 (VEGFR3). This agent may both inhibit angiogenesis and halt tumor cell growth. Check for active clinical trials or closed clinical trials using this agent. (NCI Thesaurus). (Last update: 7/2/2015). Synonym: AL3818, AL-3818, AL 3818, Anlotinib - IUPAC/Chemical Name: NONE
CAS
1058156-90-3
Created by admin on Sat Jun 26 09:23:46 UTC 2021 , Edited by admin on Sat Jun 26 09:23:46 UTC 2021
PRIMARY
ChEMBL
CHEMBL3545021
Created by admin on Sat Jun 26 09:23:46 UTC 2021 , Edited by admin on Sat Jun 26 09:23:46 UTC 2021
PRIMARY
PUBCHEM
25017411
Created by admin on Sat Jun 26 09:23:46 UTC 2021 , Edited by admin on Sat Jun 26 09:23:46 UTC 2021
PRIMARY
INN
11077
Created by admin on Sat Jun 26 09:23:46 UTC 2021 , Edited by admin on Sat Jun 26 09:23:46 UTC 2021
PRIMARY
Related Record Type Details
ACTIVE MOIETY
Results: Dose-limiting toxicities (DLT) at the 10mg/d for consecutive 4 weeks group was grade 3 hypertension, and significant accumulation of anlotinib was observed. For 2 weeks on/1 week off group, DLT were grade 3 hypertension and grade 3 fatigue at the dose of 16 mg/d, the maximum-tolerated doses (MTD) was 12mg/d, the plasma concentration of anlotinib was well controlled. Anlotinib reached its maximum plasma concentration with Tmax of 411 h after orally administration at 10, 12, or 16 mg/subject. Then it eliminated slowly with t1/2of 64136 h and MRT of 124167 h. 20 patients of the 21 patients at the dose of 12mg/d (2 weeks on/1 week off) were assessable for efficacy, 3 patients had a partial response(include renal cancer(n = 2), and soft tissue tumor),14 patients had stable disease(include medullary carcinoma of thyroid, NSCLC, colon cancer, melanoma, thymic carcinoma, and adenoid cystic carcinoma), with 9 patients lasting > 72 weeks. Official Title: A Phase I Study of Anlotinib on Tolerance and Pharmacokinetics Purpose: Anlotibib (ALTN) is a kind of innovative medicines approved by State Food and Drug AdministrationSFDA which was researched by Jiangsu Chia-tai Tianqing Pharmaceutical Co., Ltd. ALTN is a kinase inhibitor of receptor tyrosine with multi-targets, especially for VEGFR2 and VEGFR3. It has the obvious resistance to new angiogenesis. Drug: Anlotinib(Primary); Indication: Renal cell carcinoma; Focus: Therapeutic Use; Sponsor: Chia Tai Tianqing Pharmaceutical Group; Most Recent Events: 25 Apr 2016 Planned End Date changed from 1 Dec 2015 to 1 Dec 2016., 25 Apr 2016 Planned primary completion date changed from 1 Dec 2015 to 1 Dec 2016., 22 Oct 2015 Status changed from recruiting to active, no longer recruiting, as reported by ClinicalTrials.gov.